Vascular endothelial growth factor expression is unaltered in placentae and myometrial resistance arteries from pre-eclamptic patients

Acta Obstetricia et Gynecologica Scandinavica

Volumn 85, Issue 5, 2006, Pages 545-550

  Oh, Min Jeong ^a   Kwan Lee, Jae ^a   Woo Lee, Nak ^a   Shin, Jung Ho ^a   Koo Yeo, Min ^a   Kim, Aeree ^a   Sun Kim, In ^a   Kim, Hai Joong ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Perivascular smooth muscle; Pre eclampsia; VEGF

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MYOMETRIUM; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE FIBER; SYNCYTIOTROPHOBLAST; UTERINE ARTERY; ARTERY; BLOOD; CASE CONTROL STUDY; CYTOLOGY; MATERNAL AGE; METABOLISM; PARITY; PREGNANCY; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ADULT; ARTERIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MATERNAL AGE; MUSCLE, SMOOTH, VASCULAR; MYOMETRIUM; PARITY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR RESISTANCE;

EID: 33744997641     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340500405818     Document Type: Article

References (19)

1. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-32.
2. Baker PN, Krasnow J, Roberts JM, Yeo KT. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol. 1995;86:815-21.
3. Sharkey AM, Cooper JC, Balmforth JR, Mclaren J, Clark DE, Charnock-Jones DS, et al. Maternal plasma levels of vascular endothelial growth factor in patients with preeclampsia. Eur J Clin Invest. 1996;26:1182-5.
4. Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol. 1997;38:302-6.
5. Brockelsby JC, Anthony F, Johnson IRJ, Wheeler T, Baker PN. Increased serum vascular endothelial growth factor concentrations in pre-eclampsia. Hypertens Pregnancy. 1998;17:283-90.
6. Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in preeclampsia. Br J Obstet Gynecol. 1997;104:223-8.
7. Reuvekamp A, Velsing-Aarts FV, Poulina IEJ, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynecol. 1999;106:1019-22.
8. Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynecol. 1996;103:1191-6.
9. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab. 2002;87:4213-24.
10. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88:5555-63.
11. Ranheim T, Staff AC, Henriksen T. VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery. Acta Obstet Gynecol Scand. 2001;80:93-8.
12. Sgambati E, Marini M, Thyrion GDZ, Parretti E, Mello G, Orlando C, et al. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. Br J Obstet Gynecol. 2004;111:564-70.
13. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med. 1997;3:879-86.
14. Wheeler TW, Evans PW, Anthony FW, Godfrey KM, Howe DT, Osmond C. Relationship between maternal serum vascular endothelial growth factor concentration in early pregnancy and fetal and placental growth. Hum Reprod. 1999;14:1619-23.
15. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001;26:25-35.
16. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-58.
17. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with pre-eclampsia. J Clin Endocrinol Metab. 2003;88:2348-51.
18. Levine RJ, Maynard SE, Qian C, Lim KH, England L, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.
19. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Kim YM, Goncalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol. 2004;190:1547-50.